139 related articles for article (PubMed ID: 18411458)
21. FDA notifications. Abbott sends out provider letter about Kaletra for kids.
AIDS Alert; 2007 Oct; 22(10):118. PubMed ID: 18416010
[No Abstract] [Full Text] [Related]
22. Seldane warnings.
Vazquez E; Whitfield L
Posit Aware; 1997; 8(6):12. PubMed ID: 11364851
[TBL] [Abstract][Full Text] [Related]
23. FDA notifications. Atazanavir capsule label is updated for pediatric patients.
AIDS Alert; 2008 May; 23(5):59-60. PubMed ID: 18637262
[No Abstract] [Full Text] [Related]
24. FDA notifications. Norvir label changes approved.
AIDS Alert; 2008 Oct; 23(10):115-6. PubMed ID: 18938256
[No Abstract] [Full Text] [Related]
25. The Sporicidin recall.
Healthc Hazard Mater Manage; 1992 Jan; 5(4):9-11. PubMed ID: 10116667
[TBL] [Abstract][Full Text] [Related]
26. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
Struve CT
Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
[No Abstract] [Full Text] [Related]
27. New law gives FDA more influence to monitor drug safety.
Wadman M
Nat Med; 2007 Nov; 13(11):1269. PubMed ID: 17987008
[No Abstract] [Full Text] [Related]
28. The FDA continues to monitor dental amalgam use.
Dent Today; 2002 Apr; 21(4):38, 40-1. PubMed ID: 11957232
[No Abstract] [Full Text] [Related]
29. Should hospitals report to the FDA?
McNaughton DJ
Healthc Comput Commun; 1987 Oct; 4(10):29. PubMed ID: 10288562
[No Abstract] [Full Text] [Related]
30. Leavitt: reforms will improve oversight and openness at FDA.
FDA Consum; 2005; 39(3):37. PubMed ID: 16127819
[TBL] [Abstract][Full Text] [Related]
31. Dr. Hayes on the new FDA.
Hayes AH
Med World News; 1982 Nov; 23(24):49-51, 54-6. PubMed ID: 10257598
[No Abstract] [Full Text] [Related]
32. MedWatch: managing risks at the FDA.
Meadows M
FDA Consum; 2003; 37(5):10-1. PubMed ID: 14666899
[No Abstract] [Full Text] [Related]
33. FDA approves marketing of diclofenac.
Clin Pharm; 1988 Nov; 7(11):785. PubMed ID: 3197378
[No Abstract] [Full Text] [Related]
34. FDA urges reports on stapler incidents.
OR Manager; 2004 Jan; 20(1):6. PubMed ID: 14740469
[No Abstract] [Full Text] [Related]
35. Fort Dodge recalls ProHeart 6, citing FDA safety concerns. Advisory committee to review FDA findings.
Kuehn BM
J Am Vet Med Assoc; 2004 Oct; 225(8):1157-8. PubMed ID: 15521431
[No Abstract] [Full Text] [Related]
36. "Substantially equivalent": the FDA, orthopedic device manufacturer, and you.
Shaw JA
J Arthroplasty; 2005 Jan; 20(1):1-3. PubMed ID: 15660052
[No Abstract] [Full Text] [Related]
37. The FDA animal efficacy rule and biodefense.
Gronvall GK; Trent D; Borio L; Brey R; Nagao L;
Nat Biotechnol; 2007 Oct; 25(10):1084-7. PubMed ID: 17921984
[No Abstract] [Full Text] [Related]
38. FDA alert: protease inhibitors reportedly cause bleeding.
AIDS Patient Care STDS; 1996 Dec; 10(6):378. PubMed ID: 11361567
[No Abstract] [Full Text] [Related]
39. FDA notifications. FDA approves generic lamivudine.
AIDS Alert; 2008 Dec; 23(12):142. PubMed ID: 19110688
[No Abstract] [Full Text] [Related]
40. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
